Identification of a subgroup of patients with high-risk diffuse large B cell lymphoma that could benefit from treatment with inhibitor targeting iron metabolism (Ironomycin). J. Moreaux, R. Rodriguez, J. Devin, C. Bret, T. Cañeque. WO2021089819
Brag2 inhibitors and applications thereof. M. Zeghouf, R. Rodriguez.; J Cherfils, A. Nawrotek, S. Benabdi, S. Niyomchon. WO2020016239
New compounds with biguanidyl radical and uses therefof. S. Müller, T. Cañeque, R. Rodriguez. WO2019233982
Total cellular iron as a marker of cancer stem cells and uses thereof. T. Mai, A. Hamaï, M. Mehrpour, R. Rodriguez. WO2017153475
Visual detection of platinated DNA lesions from a clickable cisplatin probe used as diagnostic tool or to identify synergistic treatments. E. Zacharioudakis, L. Kunalingam, P. Agarwal, A. Bartoli, K. M. Miller, R. Rodriguez. WO2017102934
Nitrogen-containing analogs of salinomycin, synthesis and use against cancer stem cells and malaria. T. T. Mai, A. Hienzsch, A. Hamaï, M. Mehrpour, R. Rodriguez. WO2016038223
Method for preparing marmycin A and analogues thereof, and also uses thereof. T. Cañeque, F. Gomes, T. T. Mai, G. Maestri, M. Malacria, R. Rodriguez. WO2016034559
KAT inhibitors for the treatment of laminopathies, ageing and cancer. D. Larrieu, S. Britton, R. Rodriguez, S. P. Jackson. WO2015150824
